Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

被引：206

作者：

Yamazaki, K. ^{[1
]}

Nagase, M. ^{[2
]}

Tamagawa, H. ^{[3
]}

Ueda, S. ^{[4
]}

Tamura, T. ^{[5
]}

Murata, K. ^{[6
]}

Nakajima, T. Eguchi ^{[7
]}

Baba, E. ^{[8
]}

Tsuda, M. ^{[9
]}

Moriwaki, T. ^{[10
]}

Esaki, T. ^{[11
]}

Tsuji, Y. ^{[12
]}

Muro, K. ^{[13
]}

Taira, K. ^{[14
]}

Denda, T. ^{[15
]}

Funai, S. ^{[16
]}

Shinozaki, K. ^{[17
]}

Yamashita, H. ^{[18
]}

Sugimoto, N. ^{[19
]}

Okuno, T. ^{[20
]}

Nishina, T. ^{[21
]}

Umeki, M. ^{[22
]}

Kurimoto, T. ^{[23
]}

Takayama, T. ^{[24
]}

Tsuji, A. ^{[25
]}

Yoshida, M. ^{[26
]}

Hosokawa, A. ^{[27
]}

Shibata, Y. ^{[28
]}

Suyama, K. ^{[29
]}

Okabe, M. ^{[30
]}

Suzuki, K. ^{[31
]}

Seki, N. ^{[32
]}

Kawakami, K. ^{[33
]}

Sato, M. ^{[34
]}

Fujikawa, K. ^{[35
]}

Hirashima, T. ^{[36
]}

Shimura, T. ^{[37
]}

Taku, K. ^{[38
]}

Otsuji, T. ^{[39
]}

Tamura, F. ^{[40
]}

Shinozaki, E. ^{[41
]}

Nakashima, K. ^{[42
]}

Hara, H. ^{[43
]}

Tsushima, T. ^{[1
]}

Ando, M. ^{[44
]}

Morita, S. ^{[45
]}

Boku, N. ^{[7
]}

Hyodo, I. ^{[10
]}

机构：

[1] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, 1007 Shimonagakubo, Nagaizumi, Shizuoka 4118777, Japan

[2] Jichi Med Univ, Dept Clin Oncol, Shimotsuke, Japan

[3] Osaka Gen Med Ctr, Dept Surg, Osaka, Japan

[4] Kinki Univ, Dept Med Oncol, Fac Med, Higashiosaka, Osaka, Japan

[5] Kinki Univ, Dept Med Oncol, Nara Hosp, Fac Med, Ikoma, Japan

[6] Suita Municipal Hosp, Dept Surg, Suita, Osaka, Japan

[7] St Marianna Univ, Dept Clin Oncol, Sch Med, Kawasaki, Kanagawa, Japan

[8] Kyushu Univ, Dept Comprehens Clin Oncol, Fac Med Sci, Fukuoka, Japan

[9] Hyogo Canc Ctr, Dept Gastroenterol Oncol, Akashi, Hyogo, Japan

[10] Univ Tsukuba, Div Gastroenterol, Tsukuba, Ibaraki, Japan

[11] Natl Hosp Org Kyushu Canc Ctr, Dept Gastrointestinal & Med Oncol, Fukuoka, Japan

[12] Tonan Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan

[13] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[14] Osaka City Gen Hosp, Clin Oncol, Osaka, Japan

[15] Chiba Canc Ctr, Div Gastroenterol, Chiba, Japan

[16] Kinki Univ, Dept Surg, Sakai Hosp, Fac Med, Sakai, Osaka, Japan

[17] Hiroshima Prefectural Hosp, Div Clin Oncol, Hiroshima, Japan

[18] Okayama Med Ctr, Dept Gastroenterol & Hepatol, Okayama, Japan

[19] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Clin Oncol, Osaka, Japan

[20] Kobe Univ, Dept Internal Med, Div Gastroenterol, Grad Sch Med, Kobe, Hyogo, Japan

[21] Natl Hosp Org Shikoku Canc Ctr, Dept Gastrointestinal Med Oncol, Matsuyama, Japan

[22] Hyogo Prefectural Awaji Med Ctr, Dept Surg, Sumoto, Japan

[23] Nagoya Kyoritsu Hosp, Dept Gastrointestinal Oncol, Nagoya, Aichi, Japan

[24] Univ Tokushima, Dept Gastroenterol & Oncol, Grad Sch, Tokushima, Japan

[25] Kochi Hlth Sci Ctr, Dept Med Oncol, Kochi, Japan

[26] Osaka Med Coll Hosp, Div Canc Chemotherapy Ctr, Takatsuki, Osaka, Japan

[27] Toyama Univ, Dept Gastroenterol & Hematol, Fac Med, Toyama, Japan

[28] Miyazaki Prefectural Miyazaki Hosp, Dept Chemotherapy, Miyazaki, Japan

[29] Toranomon Gen Hosp, Dept Med Oncol, Tokyo, Japan

[30] Kurashiki Cent Hosp, Dept Surg, Kurashiki, Okayama, Japan

[31] Kushiro City Gen Hosp, Dept Gastroenterol, Kushiro, Hokkaido, Japan

[32] Teikyo Univ, Dept Internal Med, Div Med Oncol, Sch Med, Tokyo, Japan

[33] Muroran City Gen Hosp, Dept Gastroenterol, Muroran, Hokkaido, Japan

[34] Ryuugasaki Saiseikai Hosp, Dept Gastroenterol & Hepatol, Ryugasaki, Japan

[35] Hokkaido Canc Ctr, Dept Gastroenterol, Sapporo, Hokkaido, Japan

[36] Osaka Prefectural Med Ctr Resp & Allerg Dis, Dept Thorac Malignancy, Habikino, Japan

[37] Nagoya City Univ, Dept Gastroenterol & Metab, Grad Sch Med Sci, Nagoya, Aichi, Japan

[38] Shizuoka Prefectural Gen Hosp, Div Med Oncol, Shizuoka, Japan

[39] Dongo Hosp, Dept Gastroenterol, Yamatotakada, Japan

[40] Kumamoto Reg Med Ctr, Dept Gastroenterol, Kumamoto, Japan

[41] Canc Inst Hosp JFCR, Dept Gastroenterol, Tokyo, Japan

[42] Miyazaki Univ, Dept Internal Med 1, Fac Med, Miyazaki, Japan

[43] Saitama Canc Ctr, Dept Gastroenterol, Saitama, Japan

[44] Nagoya Univ Hosp, Ctr Adv Med & Clin Res, Nagoya, Aichi, Japan

[45] Kyoto Univ, Dept Biomed Stat & Bioinformat, Grad Sch Med, Kyoto, Japan

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷 / 08期

关键词：

irinotecan; oxaliplatin; bevacizumab; colorectal cancer; phase III study; CONTROLLED-TRIAL; OPEN-LABEL; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; IRINOTECAN; CHEMOTHERAPY; COMBINATION; CETUXIMAB; THERAPY;

D O I：

10.1093/annonc/mdw206

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This randomized phase III trial compared FOLFIRI plus bevacizumab with mFOLFOX6 plus bevacizumab as the first-line treatment for patients with metastatic colorectal cancer. This direct comparative phase III trial demonstrated that FOLFIRI plus bevacizumab was non-inferior to mFOLFOX6 plus bevacizumab in terms of progression-free survival, and was associated with favorable quality of life profiles.FOLFIRI and FOLFOX have shown equivalent efficacy for metastatic colorectal cancer (mCRC), but their comparative effectiveness is unknown when combined with bevacizumab. WJOG4407G was a randomized, open-label, phase III trial conducted in Japan. Patients with previously untreated mCRC were randomized 1:1 to receive either FOLFIRI plus bevacizumab (FOLFIRI + Bev) or mFOLFOX6 plus bevacizumab (mFOLFOX6 + Bev), stratified by institution, adjuvant chemotherapy, and liver-limited disease. The primary end point was non-inferiority of FOLFIRI + Bev to mFOLFOX6 + Bev in progression-free survival (PFS), with an expected hazard ratio (HR) of 0.9 and non-inferiority margin of 1.25 (power 0.85, one-sided alpha-error 0.025). The secondary end points were response rate (RR), overall survival (OS), safety, and quality of life (QoL) during 18 months. This trial is registered to the University Hospital Medical Information Network, number UMIN000001396. Among 402 patients enrolled from September 2008 to January 2012, 395 patients were eligible for efficacy analysis. The median PFS for FOLFIRI + Bev (n = 197) and mFOLFOX6 + Bev (n = 198) were 12.1 and 10.7 months, respectively [HR, 0.905; 95% confidence interval (CI) 0.723-1.133; P = 0.003 for non-inferiority]. The median OS for FOLFIRI + Bev and mFOLFOX6 + Bev were 31.4 and 30.1 months, respectively (HR, 0.990; 95% CI 0.785-1.249). The best overall RRs were 64% for FOLFIRI + Bev and 62% for mFOLFOX6 + Bev. The common grade 3 or higher adverse events were leukopenia (11% in FOLFIRI + Bev/5% in mFOLFOX6 + Bev), neutropenia (46%/35%), diarrhea (9%/5%), febrile neutropenia (5%/2%), peripheral neuropathy (0%/22%), and venous thromboembolism (6%/2%). The QoL assessed by FACT-C (TOI-PFC) and FACT/GOG-Ntx was favorable for FOLFIRI + Bev during 18 months. FOLFIRI plus bevacizumab was non-inferior for PFS, compared with mFOLFOX6 plus bevacizumab, as the first-line systemic treatment for mCRC. UMIN000001396.

引用

页码：1539 / 1546

页数：8

共 50 条

[21] PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer
Yoshino, Takayuki
Uetake, Hiroyuki
Tsuchihara, Katsuya
Shitara, Kohei
Yamazaki, Kentaro
Watanabe, Jun
Oki, Eiji
Sato, Takeo
Naitoh, Takeshi
Komatsu, Yoshito
Kato, Takeshi
Mori, Ikuo
Yamanaka, Kazunori
Hihara, Masamitsu
Soeda, Junpei
Yamanaka, Takeharu
Akagi, Kiwamu
Ochiai, Atsushi
Muro, Kei
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[22] PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer
Muro, Kei
Uetake, Hiroyuki
Tsuchihara, Katsuya
Shitara, Kohei
Yamazaki, Kentaro
Oki, Eiji
Sato, Takeo
Naitoh, Takeshi
Komatsu, Yoshito
Kato, Takeshi
Iwasaki, Kouji
Soeda, Junpei
Hihara, Masamitsu
Yamanaka, Takeharu
Ochiai, Atsushi
Yoshino, Takayuki
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[23] PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer
Muro, K.
Uetake, H.
Tsuchihara, K.
Shitara, K.
Yamazaki, K.
Ota, M.
Oki, E.
Sato, T.
Naitoh, T.
Komatsu, Y.
Kato, T.
Yamanaka, K.
Mori, I.
Soeda, J.
Hihara, M.
Yamanaka, T.
Akagi, K.
Ochiai, A.
Yoshino, T.
ANNALS OF ONCOLOGY, 2019, 30
[24] Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
Eiji Oki
Yasunori Emi
Takeharu Yamanaka
Hiroyuki Uetake
Kei Muro
Takao Takahashi
Takeshi Nagasaka
Etsuro Hatano
Hitoshi Ojima
Dai Manaka
Tetsuya Kusumoto
Yu Katayose
Toshiyoshi Fujiwara
Kazuhiro Yoshida
Michiaki Unno
Ichinosuke Hyodo
Naohiro Tomita
Kenichi Sugihara
Yoshihiko Maehara
British Journal of Cancer, 2019, 121 : 222 - 229
[25] FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study
Iwamoto, S.
Takahashi, T.
Tamagawa, H.
Nakamura, M.
Munemoto, Y.
Kato, T.
Hata, T.
Denda, T.
Morita, Y.
Inukai, M.
Kunieda, K.
Nagata, N.
Kurachi, K.
Ina, K.
Ooshiro, M.
Shimoyama, T.
Baba, H.
Oba, K.
Sakamoto, J.
Mishima, H.
ANNALS OF ONCOLOGY, 2015, 26 (07) : 1427 - 1433
[26] A randomized, phase IIb study of sunitinib plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) versus bevacizumab plus mFOLFOX6 ns first-line treatment for metastatic colorectal cancer (mCRC); Interim results.
Hecht, J. R.
Yoshio, T.
Mitchell, E. P.
Dees, M. S., III
Countouriotis, A. M.
Maneval, E. C.
Kretzschmar, A.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[27] Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
Oki, Eiji
Emi, Yasunori
Yamanaka, Takeharu
Uetake, Hiroyuki
Muro, Kei
Takahashi, Takao
Nagasaka, Takeshi
Hatano, Etsuro
Ojima, Hitoshi
Manaka, Dai
Kusumoto, Tetsuya
Katayose, Yu
Fujiwara, Toshiyoshi
Yoshida, Kazuhiro
Unno, Michiaki
Hyodo, Ichinosuke
Tomita, Naohiro
Sugihara, Kenichi
Maehara, Yoshihiko
BRITISH JOURNAL OF CANCER, 2019, 121 (03) : 222 - 229
[28] A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients
Nishina, Tomohiro
Takano, Yoshinao
Denda, Tadamichi
Yasui, Hisateru
Takeda, Koji
Ura, Takashi
Esaki, Taito
Okuyama, Yusuke
Kondo, Ken
Takahashi, Yasuo
Sugiyama, Yasuyuki
Muro, Kei
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (11) : 1080 - 1086
[29] MFOLFOX6 plus CEDIRANIB VS MFOLFOX6 plus BEVACIZUMAB IN PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC): A RANDOMIZED, DOUBLE-BLIND, PHASE II/III STUDY (HORIZON III)
Schmoll, H.
Cunningham, D.
Sobrero, A.
Karapetis, C.
Rougier, P.
Koski, S. L.
Barker, P.
Mookerjee, B.
Robertson, J.
van Cutsem, E.
ANNALS OF ONCOLOGY, 2010, 21 : 189 - 189
[30] Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer
Bayoglu, Ibrahim Vedat
Yildiz, Ibrahim
Varol, Umut
Cokmert, Suna
Kucukzeybek, Yuksel
Alacacioglu, Ahmet
Demir, Lutfiye
Dirican, Ahmet
Akyol, Murat
Yildiz, Yasar
Tarhan, Mustafa Oktay
JOURNAL OF BUON, 2015, 20 (02): : 460 - 467

← 1 2 3 4 5 →